TORONTO--(BUSINESS WIRE)--Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, is pleased to announce that it will participate and present at the Bloom Burton & Co. Healthcare Conference in Toronto on April 30th to May 1st, 2019.
Mr. Bill Leonard, President and Chief Executive Officer will present a corporate overview and the Company’s growth plans for 2019 and beyond.
Greenbrook’s presentation details are:
When: Wednesday May 1st, 2019
Time: 10:30 a.m. Eastern time
Where: Metro Toronto Convention Centre, 255 Front Street West, Toronto, Ontario
About the Conference
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and International investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.
About Bloom Burton & Co.
Bloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF).
About Greenbrook TMS Inc.
Operating through 70 Company-operated treatment centers, Greenbrook is a leading provider of TMS, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 220,000 TMS treatments to over 6,000 patients struggling with depression.